A once-weekly injection consisting of a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg (Wegovy) led to ...

Shares of Novo Nordisk (CSE: NOVOb) continued their upward momentum on Tuesday, rising over 5%, following gains on Monday.

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Evercore ISI raised the firm’s price target on Ascendis Pharma (ASND) to $220 from $205 and keeps an Outperform rating on the shares. The ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Ascendis Pharma (ASND) announced that YORVIPATH is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone, administered once-daily, designed to ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, ...

Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...

Concurrent with its investment, Miriam Frieden, Novo Nordisk’s Corporate Vice President of Early Innovation, Outreach and Alliances will join Eikonizo’s Board of Directors as a non-voting ...